Designing antibodies as therapeutics

PJ Carter, A Rajpal - Cell, 2022 - cell.com
Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

[HTML][HTML] Pulmonary delivery of biological drugs

W Liang, HW Pan, D Vllasaliu, JKW Lam - Pharmaceutics, 2020 - mdpi.com
In the last decade, biological drugs have rapidly proliferated and have now become an
important therapeutic modality. This is because of their high potency, high specificity and …

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2

Y Xiang, S Nambulli, Z Xiao, H Liu, Z Sang, WP Duprex… - Science, 2020 - science.org
Cost-effective, efficacious therapeutics are urgently needed to combat the COVID-19
pandemic. In this study, we used camelid immunization and proteomics to identify a large …

SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2

Q Lu, J Liu, S Zhao, MFG Castro, M Laurent-Rolle… - Immunity, 2021 - cell.com
Despite mounting evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) engagement with immune cells, most express little, if any, of the canonical receptor of …

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

TJ Esparza, NP Martin, GP Anderson, ER Goldman… - Scientific Reports, 2020 - nature.com
There are currently few approved effective treatments for SARS-CoV-2, the virus responsible
for the COVID-19 pandemic. Nanobodies are 12–15 kDa single-domain antibody fragments …

Advances in nanomaterial-based platforms to combat COVID-19: Diagnostics, preventions, therapeutics, and vaccine developments

N Mahmud, MI Anik, MK Hossain, MI Khan… - ACS Applied Bio …, 2022 - ACS Publications
The COVID-19 pandemic caused by the SARS-CoV-2, a ribonucleic acid (RNA) virus that
emerged less than two years ago but has caused nearly 6.1 million deaths to date. Recently …

Nanobodies: robust miniprotein binders in biomedicine

JYJ Kim, Z Sang, Y Xiang, Z Shen, Y Shi - Advanced Drug Delivery …, 2023 - Elsevier
Variable domains of heavy chain-only antibodies (VHH), also known as nanobodies (Nbs),
are monomeric antigen-binding domains derived from the camelid heavy chain-only …

COVID-19 diagnosis: current and future techniques

A Sharma, S Balda, M Apreja, K Kataria… - International Journal of …, 2021 - Elsevier
COVID-19 pandemic continues to be a global threat, affecting more than 200
countries/territories at both human and economic level. This necessitates the rapid …

Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy

C Cruz-Teran, K Tiruthani, M McSweeney, A Ma… - Advanced drug delivery …, 2021 - Elsevier
To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …

Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions

E Gavor, YK Choong, SY Er, H Sivaraman… - Trends in …, 2020 - cell.com
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …